It is generally accepted that the first successful organ transplant was the one performed by Dr. Joseph E. Murray at Peter Bent Brigham Hospital in Boston in 1954. Dr. Murray, who won the Nobel Prize for Medicine in 1990, and … Continue reading →

A publicly-traded biotech company, International Stem Cell Corporation (OTCQB: ISCO) focuses its efforts toward developing innovative solutions that advance the field of regenerative medicine. This field strives to create functional tissue to repair and replace tissue or organs that have … Continue reading →

The entry on International Stem Cell Corporation (OTCQB: ISCO) in the SAGE Encyclopedia tells a bit of the company’s story. At first, the researchers at ISCO were working on finding a stem cell treatment for diabetes, but ‘in the process … Continue reading →

Human embryonic stem cells typically come from fertilized eggs. International Stem Cell Corp. (OTCQB: ISCO) uses a process called parthenogenesis, in which researchers use chemicals to induce the egg to begin developing as if it had been fertilized. The egg … Continue reading →

Before the opening bell, International Stem Cell Corporation (OTCQB: ISCO) provided a business update and announced its fourth quarter and year-end financial results for the period ended December 31, 2015. Through wholly-owned subsidiaries Lifeline Skin Care and Lifeline Cell Technology, … Continue reading →

International Stem Cell Corporation (OTCQB: ISCO) is a company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development of cell-based research and cosmetic products leading to commercialization. ISCO’s core technology, parthenogenesis, is achieved through the … Continue reading →

We are apt to scoff at stories of virgin birth, and the term itself is something of an oxymoron, since the virgin usually has had some ‘knowledge’ of a male progenitor. Many of the classical Greco-Roman heroes, like Hercules, who … Continue reading →

International Stem Cell Corporation (OTCQB: ISCO) builds shareholder value through its research with stem cells, otherwise known as cells that can both proliferate (divide) and change (differentiate) into more specialized cells, such as skin, nerve or liver cells. The most … Continue reading →

Before the opening bell, International Stem Cell Corporation (OTCQB: ISCO) announced entry into a definitive agreement with two institutional healthcare investors and its management team through which the company will raise $6.3 million to fund its upcoming phase I study … Continue reading →

Before the opening bell, International Stem Cell Corporation (OTCQB: ISCO) took a major step in the development of its human parthenogenetic stem cell-derived neural stem cells (ISC-hpNSC) for the treatment of moderate to severe Parkinson’s disease when it announced the … Continue reading →